Last reviewed · How we verify
NCT03908307
Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
Phase 4 trial testing OZURDEX in Macular Edema in 150 participants. Completed in 26 September 2021.
26 September 2021
Quick facts
| Lead sponsor | Allergan |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 25 July 2019 |
| Primary completion | 26 September 2021 |
| Estimated completion | 26 September 2021 |
| Sites | 9 locations across China |
Drugs / interventions tested
- OZURDEX — full drug profile →
Conditions studied
- Macular Edema — all drugs for Macular Edema →
- Retinal Vein Occlusion — all drugs for Retinal Vein Occlusion →
Sponsor
Allergan — full company profile →
Who can join
18 and older, any sex, with Macular Edema or Retinal Vein Occlusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03908307
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Macular Edema
Currently open trials in the same condition.
- NCT06962839 — A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema · Phase 2 · recruiting
- NCT06686641 — Incidence of Macular Edema in a Uveitis Population · active not recruiting
- NCT05976139 — Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies · NA · recruiting
- NCT05698329 — Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macula · Phase 1 · active not recruiting
- NCT06595355 — Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin · Phase 2, PHASE3 · recruiting
Other Allergan trials
Trials by the same sponsor.
- NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment · Phase 4 · completed
- NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft · Phase 3 · completed
- NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi · Phase 2 · withdrawn
- NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi · Phase 2 · completed
- NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03908307 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Allergan
- Last refreshed: 31 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03908307.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing